CIRCULATING ANGIOTENSIN-II LEVELS UNDER REPEATED ADMINISTRATION OF LISINOPRIL IN NORMAL SUBJECTS

被引:21
作者
KAWAMURA, M
IMANASHI, M
MATSUSHIMA, Y
ITO, K
HIRAMORI, K
机构
[1] YOHKAICHI NATL HOSP,SHIGA,JAPAN
[2] NATL CARDIOVASC CTR,DIV HYPERTENS,SUITA,OSAKA 565,JAPAN
关键词
ANGIOTENSIN I-CONVERTING ENZYME; ANGIOTENSIN-II; BLOOD PRESSURE; LISINOPRIL; WITHDRAWAL;
D O I
10.1111/j.1440-1681.1992.tb00503.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. To examine the effect of chronic administration of angiotensin I-converting enzyme (ACE) inhibitor on circulating angiotensin II (AII) concentration, 20 mg of lisinopril was administered once daily for 7 consecutive days to eight healthy volunteers. 2. Plasma ACE activity was inhibited to less than approximately 30% of the pretreatment level during the repeated administration. 3. Mean arterial pressure (MAP) was slightly but significantly reduced during the administration period. Plasma AII concentration measured by an established method using high performance liquid chromatography combined with a radioimmunoassay, however, was maintained at approximately the pretreatment level when it was measured at 24 h intervals after each administration of lisinopril. 4. With the gradual recovery of ACE activity following discontinuation of administration, the plasma AII concentration correlated with AI concentration (r = 0.46), and also with the product of AI and ACE activity (AI X ACE; r = 0.80), corresponding to the formula obtained from the kinetics of ACE activity. No correlation was observed between MAP and AII levels throughout the study period. 5. We conclude that in normal subjects repeatedly administered with ACE inhibitor, the AII level in the circulation is still determined by an elevated level of AI and any remaining ACE activity, thus maintaining AII at pretreatment levels. We confirmed that it is not necessary to achieve a decrease in plasma AII concentration through the chronic administration of ACE inhibitor in order to effectively lower blood pressure.
引用
收藏
页码:547 / 553
页数:7
相关论文
共 31 条
  • [1] METABOLISM AND PRODUCTION OF ANGIOTENSIN-I IN DIFFERENT VASCULAR BEDS IN SUBJECTS WITH HYPERTENSION
    ADMIRAAL, PJJ
    DERKX, FHM
    DANSER, AHJ
    PIETERMAN, H
    SCHALEKAMP, MADH
    [J]. HYPERTENSION, 1990, 15 (01) : 44 - 55
  • [2] ANTIHYPERTENSIVE THERAPY WITH MK-421 - ANGIOTENSIN-II-RENIN RELATIONSHIPS TO EVALUATE EFFICACY OF CONVERTING ENZYME BLOCKADE
    BIOLLAZ, J
    BRUNNER, HR
    GAVRAS, I
    WAEBER, B
    GAVRAS, H
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1982, 4 (06) : 966 - 972
  • [3] CACEST R, 1974, AUSTR J EXPT BIOL ME, V52, P601
  • [4] CAMPBELL D J, 1987, Journal of Cardiovascular Pharmacology, V10, pS1
  • [5] SIMULTANEOUS RADIOIMMUNOASSAY OF 6 ANGIOTENSIN PEPTIDES IN ARTERIAL AND VENOUS PLASMA OF MAN
    CAMPBELL, DJ
    KLADIS, A
    [J]. JOURNAL OF HYPERTENSION, 1990, 8 (02) : 165 - 172
  • [6] POSSIBLE ROLE OF RENIN IN HYPERTENSION AS SUGGESTED BY RENIN-SODIUM PROFILING AND INHIBITION OF CONVERTING ENZYME
    CASE, DB
    WALLACE, JM
    KEIM, HJ
    WEBER, MA
    SEALEY, JE
    LARAGH, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1977, 296 (12) : 641 - 646
  • [7] GADSBOLL N, 1986, J HYPERTENS, V4, pS474
  • [8] ANTIHYPERTENSIVE EFFECT OF ORAL ANGIOTENSIN CONVERTING-ENZYME INHIBITOR SQ 14225 IN MAN
    GAVRAS, H
    BRUNNER, HR
    TURINI, GA
    KERSHAW, GR
    TIFFT, CP
    CUTTELOD, S
    GAVRAS, I
    VUKOVICH, RA
    MCKINSTRY, DN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1978, 298 (18) : 991 - 995
  • [9] Giese J, 1983, J Hypertens Suppl, V1, P31
  • [10] ENALAPRIL (MK421) AND ITS LYSINE ANALOG (MK521) - A COMPARISON OF ACUTE AND CHRONIC EFFECTS ON BLOOD-PRESSURE, RENINANGIOTENSIN SYSTEM AND SODIUM-EXCRETION IN NORMAL MAN
    HODSMAN, GP
    ZABLUDOWSKI, JR
    ZOCCALI, C
    FRASER, R
    MORTON, JJ
    MURRAY, GD
    ROBERTSON, JIS
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 17 (03) : 233 - 241